Question 1

How reliable is computational epitope prediction?

Accepted Answer

Prediction identifies peptides likely to bind presentation molecules, which is necessary but far from sufficient. Many predicted sequences never provoke a response because processing does not generate them or because tolerance suppresses reactive cells. Use prediction to prioritise regions for laboratory testing rather than as a risk estimate in itself.

Question 2

What does peptide presentation profiling add?

Accepted Answer

Incubating the product with antigen-presenting cells and then identifying the peptides actually displayed shows which sequences survive processing, which prediction cannot. This narrows candidate epitopes substantially before donor assays begin, and it catches junction sequences in engineered formats that no natural protein contains.

Question 3

How should a donor panel be assembled?

Accepted Answer

Responses depend on the presentation molecules each donor carries, so the panel must cover the tissue type diversity of the intended patient population, including groups often under-represented in convenience sampling. Report the tissue types included and the number of donors, since a response frequency from an unrepresentative panel misleads.

Question 4

How is an anti-drug antibody assay structured?

Accepted Answer

A sensitive screening step flags potential positives, a confirmation step using competition with excess product removes false signals, and titration quantifies the response. Positives then move to a neutralising assay. Establish the screening cut point from drug-naive samples using a defined statistical approach and report it.

Question 5

Why does drug interference matter so much?

Accepted Answer

Product circulating in the sample binds the antibodies being measured and hides them, so apparent negatives may simply reflect timing. Acid dissociation, bead extraction and sampling at trough all mitigate this. Report drug tolerance of the assay at relevant antibody concentrations, because without it a negative result means little.

Question 6

Do product attributes influence risk independently of sequence?

Accepted Answer

Substantially. Aggregates present repeated arrays that stimulate responses strongly, and residual host cell proteins or other process components can act as adjuvants. Characterise aggregate content and impurity profile for the exact material used in assays, since a poorly controlled preparation exaggerates the apparent risk of the molecule itself.

Question 7

How should results be translated into a risk statement?

Accepted Answer

Combine prediction, presentation, donor response frequency and product attributes into a weighted assessment rather than relying on one output. State clearly that laboratory assays estimate relative risk between molecules and cannot predict clinical incidence, and describe what the chosen assays could not detect.

Biotechnology

Biotechnology

Research Frontiers in Immunogenicity Assessment Methods